EUVIMEDEUVIMED entdecken
Crossref

Genmab Acquires Merus for $8 Billion: The First Organoid-Discovered Clinical Asset Drives the Largest European Oncology Deal of 2025

/ /

Journal of Organoid and Bioscience · 02.03.2026 · 3 (1)

DOI: 10.62714/qclx1601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Organoid and Bioscience, online erschienen am 02.03.2026. Verfasst von / /.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COPENHAGEN & UTRECHT – September 29, 2025 – In the largest European oncology acquisition of 2025, Genmab A/S (Nasdaq: GMAB) has agreed to acquire Merus N.V. (Nasdaq: MRUS) for approximately $8 billion in cash, or $97.00 per share. The transaction instantly delivers full ownership of petosemtamab (MCLA-158), a first-in-class EGFR × LGR5 bispecific antibody that represents a historic milestone: it is the first therapeutic candidate discovered, prioritized, and advanced into Phase III clinical trials exclusively through patient-derived organoid (PDO) screening. With two FDA Breakthrough Therapy Designations already secured and Phase III trials actively enrolling globally, petosemtamab has rapidly emerged as one of the most promising investigational therapies in head-and-neck squamous cell carcinoma (HNSCC) and is projected to achieve multibillion-dollar peak sales. Breakthrough Therapy Designation is granted to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.

Zitieren

APA

/ (2026). Genmab Acquires Merus for $8 Billion: The First Organoid-Discovered Clinical Asset Drives the Largest European Oncology Deal of 2025. Journal of Organoid and Bioscience, 3(1). https://doi.org/10.62714/qclx1601

Vancouver

/. Genmab Acquires Merus for $8 Billion: The First Organoid-Discovered Clinical Asset Drives the Largest European Oncology Deal of 2025. Journal of Organoid and Bioscience. 2026;3(1). doi:10.62714/qclx1601

BibTeX
@article{2026,
  author = {/, /},
  title = {Genmab Acquires Merus for $8 Billion: The First Organoid-Discovered Clinical Asset Drives the Largest European Oncology Deal of 2025},
  journal = {Journal of Organoid and Bioscience},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.62714/qclx1601}
}
Kostenlos starten →